Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma AB held its Annual General Meeting where several key resolutions were passed, including the adoption of financial statements, re-election of board members, and approval of a long-term incentive program for employees. The meeting also authorized the board to issue new shares and warrants, providing the company with financial flexibility to pursue strategic opportunities and enhance shareholder value.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biotechnology company based in Lund, Sweden, focused on developing innovative immunomodulatory treatments for rare diseases. The company is listed on Nasdaq Stockholm and aims to address unmet medical needs through its proprietary enzyme technology platform.
Average Trading Volume: 178,868
Current Market Cap: SEK1.61B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.